Development of Generalized Myasthenia Gravis in Patients With Ocular Myasthenia Gravis
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Kupersmith et al1 provided data suggesting that low doses of corticosteroids in patients with ocular myasthenia gravis (MG) may prevent the development of generalized MG. We looked at the MG registry kept in the Department of Neurology of the University Hospital of Patras in Greece to contribute our data to this controversial issue.
Twenty-eight patients with ocular MG (grade 1 in the scale developed by Osserman and Genkins2) (mean ± SD age at diagnosis, 48.6 ± 21.5 years; range, 15-80 years; 17 [61%] men) have received follow-up for at least 8 years. Of those, 9 (32%) developed generalized MG within 2 years and 11 (39%) within 8 years of the initial diagnosis. Twenty-one patients who responded well to pyridostigmine bromide had no steroid treatment; 7 patients unresponsive to pyridostigmine were treated with prednisone. The prednisone dosage was gradually increased to 60 mg on alternate days and then gradually reduced . . . [Full Text of this Article]
T. H. Papapetropoulos, DM;
J. Ellul, DM;
E. Tsibri, MD
Patras, Greece
RELATED ARTICLE
Development of Generalized Myasthenia Gravis in Patients With Ocular Myasthenia Gravis—Reply
Peter Homel and Mark J. Kupersmith
Arch Neurol. 2003;60(10):1492-1493.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Benatar and Kaminski
Neurology 2007;68:2144-2149.
ABSTRACT
| FULL TEXT
|
